Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

Creative Commons License

KARAASLAN Z., YILMAZ V., YÜCEER H., ŞANLI E., Akcay H. I., Kurtuncu M., ...Daha Fazla

Northern Clinics of Istanbul, cilt.10, sa.3, ss.341-344, 2023 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 3
  • Basım Tarihi: 2023
  • Doi Numarası: 10.14744/nci.2022.77861
  • Dergi Adı: Northern Clinics of Istanbul
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.341-344
  • Anahtar Kelimeler: C-X-C motif chemokine 5, fingolimod, multiple sclerosis, neuromyelitis optica spectrum disorder
  • İstanbul Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.